- November 25, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Tzield,teplizumab-mzwv
Synonyms :
teplizumab-mzwv, humanized OKT3
Class :
Monoclonal antibody
Dosage Forms & Strengths
Injectable solution:
2mg/2ml single dose vial
Infusion IV over 30 minutes every day up to 14 consecutive days
Dosage regimen:
Day 1: 65 mcg/m2
Day 2: 125 mcg/m2
Day 3: 250 mcg/m2
Day 4: 500 mcg/m2
Days 5-14: 1,030 mcg/m2
Dosage Forms & Strengths
Injectable solution:
2mg/2ml single dose vial
Infusion IV over 30 minutes every day up to 14 consecutive days
Dosage regimen:
Day 1: 65 mcg/m2
Day 2: 125 mcg/m2
Day 3: 250 mcg/m2
Day 4: 500 mcg/m2
Days 5-14: 1,030 mcg/m2
Refer adult dosing
may decrease the therapeutic effect of COVID-19 vaccine
may decrease the therapeutic effect of Ebola Zaire Vaccine
choline magnesium trisalicylate
May increase the hypoglycemic effect of each other when combined
may diminish the activity of each other
may enhance the immunosuppressive effect of each other
may decrease the effect of each other
may increase the effects of each other
may diminish the activity of each other
may decrease the effects of each other
may decrease the effects of each other
may decrease the effects of each other
haemophilus influenzae type b vaccine
may decrease the effects of each other
may decrease the effects of each other
may decrease the effects of each other
may increase the effects of each other
may decrease the effects of each other
pneumococcal vaccine 13-valent
may decrease the effects of each other
pneumococcal vaccine heptavalent
may decrease the effects of each other
poliovirus vaccine inactivated
may decrease the effects of each other
may decrease the effects of each other
may decrease the effects of each other
smallpox (vaccinia) vaccine, live
may decrease the effects of each other
may enhance the immunosuppressive effect
may decrease the effects of each other
may decrease the effects of each other
may decrease the effects of each other
respiratory syncytial virus vaccine, adjuvanted
The potential efficacy of vaccines may be reduced. (Inactivated/Non-Replicating)
respiratory syncytial virus (RSV) vaccine
The potential efficacy of vaccines may be reduced. (Inactivated/Non-Replicating)
The potential efficacy of vaccines may be reduced. (Inactivated/Non-Replicating)
may decrease the therapeutic effect of corticosteroids
ciprofloxacin inhaled (Pending FDA approval)
may enhance the hypoglycemic effect of Quinolones
may diminish the therapeutic effect of hyperglycaemia associated agents
may decrease the immunosuppressive effects of each other
may decrease the receptor binding competition
Beta-blockers increase the effect of hypoglycemia of antidiabetic agents
Beta-blockers increase the effect of hypoglycemia of antidiabetic agents
Beta-blockers increase the effect of hypoglycemia of antidiabetic agents
Beta-blockers increase the effect of hypoglycemia of antidiabetic agents
Beta-blockers increase the effect of hypoglycemia of antidiabetic agents
may decrease the therapeutic effect when combined with antidiabetic agents
may decrease the therapeutic effect when combined with antidiabetic agents
may decrease the therapeutic effect when combined with antidiabetic agents
may decrease the therapeutic effect when combined with antidiabetic agents
may decrease the therapeutic effect when combined with antidiabetic agents
relugolix/estradiol/norethindrone
androgens increase the effect of hypoglycemia in these agents
relugolix/estradiol/norethindrone
androgens increase the effect of hypoglycemia in these agents
androgens increase the effect of hypoglycemia in these agents
androgens increase the effect of hypoglycemia in these agents
androgens increase the effect of hypoglycemia in these agents
It may diminish the effects when combined with rozanolixizumab by receptor binding competition
may have an increased hypoglycemic effect when combined with hypoglycemic agents
may have an increased hypoglycemic effect when combined with hypoglycemic agents
may increase the hypoglycaemic effect of androgens
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may decrease the therapeutic effect
may diminish the therapeutic effect of corticosteroids
may increase the hypoglycemic effect of quinolones
may diminish the therapeutic effect of antidiabetic agents
may diminish the therapeutic effect of antidiabetic agents
may diminish the therapeutic effect of antidiabetic agents
may diminish the therapeutic effect of antidiabetic agents
choline magnesium trisalicylate
may enhance the hypoglycemic effect
may increase the hypoglycemic effect of beta blockers
may increase the hypoglycaemic effect of beta blockers
may diminish the therapeutic effect of thiazide and thiazide like diuretics
lisinopril/hydrochlorothiazide
may enhance the serum concentration of thiazide and thiazide like diuretics
methyldopa/hydrochlorothiazide
may diminish the therapeutic effect of thiazide and thiazide like diuretics
may increase the hypoglycemic effect of direct-acting viral agents
may increase the hypoglycemic effect of direct-acting antiviral agents
may enhance the hypoglycemic effect of beta blockers
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the hypoglycemic effect of salicylates
may increase the hypoglycemic effect of hypoglycemia-associated agents
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect